|
Table 1: Main model inputs in the primary hypercholesterolemia and mixed dyslipidemia plus history of either myocardial infarction or ischemic stroke subpopulation. |
||
|
Description |
Base-case value |
Source |
|
Baseline characteristics |
||
|
Mean age (years) |
62.5 |
FOURIER trial16 |
|
Proportion of females (%) |
24.6 |
FOURIER trial16 |
|
Mean LDL-C (mg/dL) |
175.0 |
CARMELA study17 |
|
Concomitant use of ezetimibe (%) |
5.2 |
FOURIER trial16 |
|
Distribution among initial health state |
Based on the proportions of patients with a history of MI (81.1%) or of previous stroke (19.4%) in the FOURIER trial16 |
|
|
Post-MI (%) |
80.7 |
|
|
Post-IS (%) |
19.3 |
|
|
oASCVD (%) |
0.0 |
|
|
Baseline annual CV event rate* |
10.0 |
Toth et al.13 |
|
Relative reduction of LDL-C with evolocumab (%) |
59.0 |
FOURIER trial16 |
|
LDL-C = low-density lipoprotein cholesterol; MI = myocardial infarction; IS = ischemic stroke; oASCVD = other atherosclerotic cardiovascular disease; CV = cardiovascular. * Represents the rate per 100 patient-years under standard of care, calculated for a mean age of 67 years and mean LDL-C level of 103.2 mg/dL. |
||